Dexcom Presents Long-Term Data from the COMISAIR Study at EASD Demonstrating Positive Outcomes for Diabetes Patients Using CGM

Dexcom, a global leader in real-time continuous glucose monitoring (CGM) for diabetes management, unveiled multiple new clinical studies at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany. The most important data presented was from the COMISAIR study. The COMISAIR study, is the longest prospective real-world CGM study to date, and demonstrated significant and sustained reductions in HbA1c levels among individuals with Type 1 diabetes who used real-time CGM for over seven years. The study demonstrated that real-time CGM led to greater and statistically significant HbA1c reductions compared to self-monitoring blood glucose, regardless of insulin delivery method (multiple daily injections or insulin pump therapy). Additionally, substantial HbA1c reductions were observed when real-time CGM was paired with automated insulin delivery systems like Tandem Control IQ. Furthermore, the study showed high CGM adherence over seven years, regardless of insulin delivery method, 88.8% for those using CGM and multiple daily injections and 91.9% for those using CGM and automated insulin deliver (AID).

A second presented study conducted with the Dexcom ONE CGM system showcased significant reductions in HbA1c levels for individuals with both Type 1 and Type 2 diabetes on intensive or basal insulin therapies. The prospective Dexcom ONE study revealed that employing Dexcom ONE in individuals with Type 2 diabetes led to a decrease in HbA1c levels from 10.1% to 8.5% within three months, with a subsequent reduction to 8.3% at six months. This research aims to enhance access and expand reimbursement for CGM technology among people with Type 2 diabetes.

Finally, a third study presented demonstrated Dexcom’s CGM systems, including the Dexcom G7, G6, and ONE, were accurate during pregnancy for individuals with Type 1, Type 2, and gestational diabetes. Furthermore, researchers provide a review of the study protocol and objectives for the AiDAPT study, led by Helen Murphy, MBBChBAO, MD, FRACP. This study represents the largest randomized controlled trial comparing an AID system to standard insulin delivery in pregnant women with Type 1 diabetes. Early findings indicate that women using AID experience significantly more time within the target glucose range compared to those not utilizing AID.

Dexcom also announced that the Dexcom G7 CGM system is set to launch alongside the t:slim X2 insulin pump in multiple markets across the U.S., Europe, and Asia-Pacific by year-end. The t:slim X2 insulin pump is manufactured by Tandem Diabetes Care. This news also follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany earlier this year.